32 results
Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Thumbnail

D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age

Thumbnail

D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Thumbnail

D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience

Thumbnail

D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital

Thumbnail

- D3.239 - Trimethoprim-induced drug reaction with eosinophilia and systemic symptoms (DRESS) associated with reactivation of human herpesvirus-7 (HHV-7)

Thumbnail

- D3.242 - Desensitization to ampicillin fixed drug eruption. Spotting the solution to fix the heart

Thumbnail

- D3.243 - Successful subcutaneous desensitization protocols for Canakinumab, Trastuzumab, and Triptorelin: a case series report

Thumbnail

- D3.244 - Diagnosing Drug-Induced Sweet Syndrome With Target-Like Lesions Amidst Malignancy And Infection

Thumbnail

D3.245 - Positive HLA-B*13:01 Allele in a Patient with Clinical Diagnosis of Drug Induced Eosinophilia with Systemic Symptoms (DRESS)

Thumbnail

- D3.246 - Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) induced by enoxaparin: a case report and allergology work up

Thumbnail

- D3.247 - A case report of multiple drug hypersensitivity triggered by DRESS to beta-lactamase inhibitors

Thumbnail

- D3.248 - Anaphylactic shock after indocyanine green intracervical administration